Literature DB >> 8138551

3-Cyano-2,6-dihydroxypyridine (CNDP), a new potent inhibitor of dihydrouracil dehydrogenase.

K Tatsumi1, T Yamauchi, K Kiyono, K Kishi, Y Yanagihara, T Imaoka, T Kawaguchi, M Kubo.   

Abstract

3-Cyano-2,6-dihydroxypyridine (CNDP) was identified as a potent inhibitor (IC50 value, 4.4 nM) of dihydrouracil dehydrogenase (DHUDase) [EC 1.3.1.2], a rate-limiting enzyme in 5-fluorouracil (5-FU) degradation. The inhibitory activity of CNDP was about 2,000 times that of uracil under our assay conditions. Kinetic analyses with partially purified enzyme from rat liver revealed that the mechanism of inhibition of DHUDase by CNDP was of mixed type with an inhibition constant (Ki) of 1.51 nM. CNDP had less effect on 5-FU phosphorylation than on 5-FU degradation. The inhibitory effect of CNDP on ribosylation of 5-FU was 600 to 1,000 times less than that on DHUDase. Moreover, CNDP did not inhibit uridine kinase, thymidine kinase, or pyrimidine phosphoribosyltransferase. Coadministration of CNDP with 1-ethoxymethyl-5-fluorouracil (EM-FU) to rats with Yoshida sarcoma elevated the level of 5-FU in both the blood and the tumor and enhanced the antitumor effect of EM-FU. These findings indicated that CNDP would be a useful chemical modulator in chemotherapy with 5-FU or its prodrugs.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8138551     DOI: 10.1093/oxfordjournals.jbchem.a124276

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  6 in total

1.  The combined antitumour effect of a new 5-fluorouracil derivative, BOF-A2, and radiation in vivo.

Authors:  R Murata; Y Shibamoto; S Miyauchi; M Hirohashi; T Takagi; K Sasai; N Oya; M Hiraoka
Journal:  Br J Cancer Suppl       Date:  1996-07

Review 2.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

3.  Combined effect of clinically relevant doses of emitefur, a new 5-fluorouracil derivative, and radiation in murine tumours.

Authors:  Y Shibamoto; R Murata; S Miyauchi; M Hirohashi; T Takagi; K Sasai; T Shibata; N Oya; M Takahashi
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

Review 4.  Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation.

Authors:  G Milano; J-M Ferrero; E François
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640

5.  Inhibition of catabolic pathway of 5-fluorouracil by 3-cyano-2,6-dihydroxypyridine in human lung cancer tissues.

Authors:  T Okayasu; K Sugiyama; S Miyauchi
Journal:  Jpn J Cancer Res       Date:  1994-01

6.  Oral administration of BOF-A2 to rats with lung transplanted tumors results in increased 5-fluorouracil levels.

Authors:  S Miyauchi; T Imaoka; T Utsunomiya; K Hayashi; M Kubo; T Kawaguchi; Y Matsui
Journal:  Jpn J Cancer Res       Date:  1994-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.